

Stephanie Grabow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7404565/publications.pdf>

Version: 2024-02-01

31
papers

2,444
citations

361413

20
h-index

454955

30
g-index

32
all docs

32
docs citations

32
times ranked

4400
citing authors

#	ARTICLE	IF	CITATIONS
1	Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 270-281.	4.1	11
2	Combined reduction in the expression of MCL-1 and BCL-2 reduces organismal size in mice. <i>Cell Death and Disease</i> , 2020, 11, 185.	6.3	7
3	BCL-2 exerts a protective role against anemia caused by radiation-induced kidney damage. <i>EMBO Journal</i> , 2020, 39, e105561.	7.8	7
4	Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. <i>Nature Biomedical Engineering</i> , 2019, 3, 264-280.	22.5	40
5	Subtle Changes in the Levels of BCL-2 Proteins Cause Severe Craniofacial Abnormalities. <i>Cell Reports</i> , 2018, 24, 3285-3295.e4.	6.4	35
6	Embryogenesis and Adult Life in the Absence of Intrinsic Apoptosis Effectors BAX, BAK, and BOK. <i>Cell</i> , 2018, 173, 1217-1230.e17.	28.9	155
7	The rise of apoptosis: targeting apoptosis in hematologic malignancies. <i>Blood</i> , 2018, 132, 1248-1264.	1.4	107
8	Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival. <i>Journal of Experimental Medicine</i> , 2017, 214, 491-510.	8.5	66
9	Loss of BIM augments resistance of ATM-deficient thymocytes to DNA damage-induced apoptosis but does not accelerate lymphoma development. <i>Cell Death and Differentiation</i> , 2017, 24, 1987-1988.	11.2	5
10	The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice. <i>Cell Death and Differentiation</i> , 2017, 24, 2032-2043.	11.2	25
11	The BH3-only proteins BIM and PUMA are not critical for the reticulocyte apoptosis caused by loss of the pro-survival protein BCL-XL. <i>Cell Death and Disease</i> , 2017, 8, e2914-e2914.	6.3	18
12	Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis. <i>Cell Reports</i> , 2016, 14, 2337-2347.	6.4	39
13	Physiological restraint of Bak by Bcl-x _L is essential for cell survival. <i>Genes and Development</i> , 2016, 30, 1240-1250.	5.9	40
14	RAG-induced DNA lesions activate proapoptotic BIM to suppress lymphomagenesis in p53-deficient mice. <i>Journal of Experimental Medicine</i> , 2016, 213, 2039-2048.	8.5	13
15	Loss of PUMA (BBC ³) does not prevent thrombocytopenia caused by the loss of BCL-2 ^{hi} (BCL-2L1). <i>British Journal of Haematology</i> , 2016, 174, 962-969.	2.5	7
16	Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. <i>Nature Reviews Cancer</i> , 2016, 16, 99-109.	28.4	596
17	Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53. <i>Oncogene</i> , 2016, 35, 3866-3871.	5.9	33
18	Critical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis. <i>Cell Death and Disease</i> , 2016, 7, e2132-e2132.	6.3	18

#	ARTICLE	IF	CITATIONS
19	MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development. <i>Blood</i> , 2015, 125, 1910-1921.	1.4	47
20	Antagonism between MCL-1 and PUMA governs stem/progenitor cell survival during hematopoietic recovery from stress. <i>Blood</i> , 2015, 125, 3273-3280.	1.4	36
21	Impact of the combined loss of BOK, BAX and BAK on the hematopoietic system is slightly more severe than compound loss of BAX and BAK. <i>Cell Death and Disease</i> , 2015, 6, e1938-e1938.	6.3	30
22	Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4044-4049.	7.1	43
23	Functional antagonism between pro-apoptotic BIM and anti-apoptotic BCL-XL in MYC-induced lymphomagenesis. <i>Oncogene</i> , 2015, 34, 1872-1876.	5.9	21
24	Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in <i>p53</i> . <i>Genes and Development</i> , 2014, 28, 58-70.	5.9	156
25	MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in <i>p53</i> -deficient mice. <i>Blood</i> , 2014, 124, 3939-3946.	1.4	43
26	The monocytic leukaemia zinc finger (MOZ) protein is a repressor of cellular senescence, and haploinsufficiency for MOZ increases survival 3-fold in the E174-Myc lymphoma model. <i>Experimental Hematology</i> , 2013, 41, S54.	0.4	0
27	Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice. <i>Cell Death and Differentiation</i> , 2013, 20, 57-63.	11.2	16
28	Pharmacological blockade of Bcl-2, Bcl-xL and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in <i>p53</i> -deficient mice. <i>Cell Death and Differentiation</i> , 2012, 19, 623-632.	11.2	17
29	Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice. <i>Blood</i> , 2011, 118, 6380-6386.	1.4	44
30	XIAP discriminates between type I and type II FAS-induced apoptosis. <i>Nature</i> , 2009, 460, 1035-1039.	27.8	421
31	Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. <i>Nature</i> , 2009, 461, 659-663.	27.8	348